candesartan cilexetil has been researched along with Stroke in 10 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke." | 9.10 | The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. ( Berger, J; Diener, HC; Dominiak, P; Einhäupl, K; Kulschewski, A; Lüders, S; Schrader, J; Treib, J; Zidek, W, 2003) |
| "The Challenge-Stroke study was conducted in Japanese patients initiated on candesartan cilexetil therapy within 3 months of suffering a stroke to investigate the clinical use of candesartan and its efficacy/safety in this therapeutic setting." | 7.77 | Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. ( Minematsu, K; Nakagawara, J; Okada, Y; Tanahashi, N, 2011) |
| "The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke." | 5.10 | The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. ( Berger, J; Diener, HC; Dominiak, P; Einhäupl, K; Kulschewski, A; Lüders, S; Schrader, J; Treib, J; Zidek, W, 2003) |
| "The Challenge-Stroke study was conducted in Japanese patients initiated on candesartan cilexetil therapy within 3 months of suffering a stroke to investigate the clinical use of candesartan and its efficacy/safety in this therapeutic setting." | 3.77 | Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study. ( Minematsu, K; Nakagawara, J; Okada, Y; Tanahashi, N, 2011) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| "It was launched in 1998 for the treatment of hypertension." | 2.45 | Candesartan: widening indications for this angiotensin II receptor blocker? ( Mendis, B; Page, SR, 2009) |
| "Stroke is one of the leading causes of invalidism and death in the industrialized world." | 2.42 | Are angiotensin receptor blockers neuroprotective? ( Gerova, N; Krikov, M; Li, J; Neumann, C; Thöne-Reineke, C; Unger, T; Zimmermann, M, 2004) |
| "Candesartan cilexetil is a potent and long-acting blocker that, when given once a day to patients, provides effective 24 hr blood pressure control." | 2.41 | [Angiotensin II receptor antagonists: candesartan cilexetil]. ( Furukawa, Y; Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendis, B | 1 |
| Page, SR | 1 |
| Tanahashi, N | 1 |
| Nakagawara, J | 1 |
| Okada, Y | 1 |
| Minematsu, K | 1 |
| Schrader, J | 1 |
| Lüders, S | 1 |
| Kulschewski, A | 1 |
| Berger, J | 1 |
| Zidek, W | 1 |
| Treib, J | 1 |
| Einhäupl, K | 1 |
| Diener, HC | 1 |
| Dominiak, P | 1 |
| Kernan, WN | 1 |
| Michel, P | 1 |
| Bogousslavsky, J | 1 |
| Thöne-Reineke, C | 1 |
| Zimmermann, M | 1 |
| Neumann, C | 1 |
| Krikov, M | 1 |
| Li, J | 1 |
| Gerova, N | 1 |
| Unger, T | 1 |
| Fukui, T | 1 |
| Naka, T | 1 |
| Kubo, K | 1 |
| Nishikawa, K | 1 |
| Inada, Y | 1 |
| Furukawa, Y | 1 |
| Nakaya, H | 1 |
| Sasamura, H | 1 |
| Hayashi, M | 1 |
| Saruta, T | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Sato, A | 1 |
| Takagi, S | 1 |
| Tsuchiya, K | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)[NCT00108706] | Phase 4 | 50 participants | Interventional | 2004-12-31 | Active, not recruiting | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for candesartan cilexetil and Stroke
| Article | Year |
|---|---|
Candesartan: widening indications for this angiotensin II receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2009 |
Are angiotensin receptor blockers neuroprotective?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2004 |
[CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
[Angiotensin II receptor antagonists: candesartan cilexetil].
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as To | 2000 |
1 trial available for candesartan cilexetil and Stroke
| Article | Year |
|---|---|
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
Topics: Acute Disease; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2003 |
5 other studies available for candesartan cilexetil and Stroke
| Article | Year |
|---|---|
Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2011 |
Re: Evaluation of acute candesartan cilexetil therapy in stroke survivors.
Topics: Benzimidazoles; Bias; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Humans; Randomized Co | 2003 |
ACCESS study: blood pressure effect?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2002 |